🔎 Trials Near Me

Početna › Skleroderma › Illinois › Chicago

Kliničke studije za Skleroderma u gradu Chicago, IL

10 studija za Skleroderma traži sudionike na lokacijama u gradu Chicago i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.

Službeni tekst studije (engleski)

Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

U tijeku regrutacijaFaza 3
  • Northwestern University, Chicago
  • The University of Chicago Medical Center, Chicago
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07497087

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

U tijeku regrutacijaFaza 2
  • University of Illinois Health Outpatient Care Center, Chicago
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06655155

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

U tijeku regrutacijaFaza 1
  • The University of Chicago Medical Center, Chicago
Od 18 do 74 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

U tijeku regrutacijaFaza 2/3
  • GSK Investigational Site, Chicago
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT05878717

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

U tijeku regrutacijaFaza 1
  • Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Od 18 do 70 godina · Oba spola · Ažurirano 28. kol 2026. · NCT06925542

Platform Clinical Study for Conquering Scleroderma

U tijeku regrutacijaFaza 2
  • The University of Chicago Medical Center (UCMC), Chicago
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

U tijeku regrutacijaFaza 2/3
  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
Od 18 do 75 godina · Oba spola · Ažurirano 17. kol 2026. · NCT06328777

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

U tijeku regrutacijaFaza 1/2
  • Nkarta Investigational Site, Chicago
Od 18 do 75 godina · Oba spola · Ažurirano 7. kol 2026. · NCT06733935

A Study of AZD0120 in Autoimmune Diseases

U tijeku regrutacijaFaza 1
  • Research Site, Chicago
Od 18 do 75 godina · Oba spola · Ažurirano 28. srp 2026. · NCT07295847

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

U tijeku regrutacijaFaza 2
  • aTyr Investigative Site, Chicago
  • aTyr Investigative Site, Chicago
  • aTyr Investigative Site, Chicago
Od 18 godina i više · Oba spola · Ažurirano 7. svi 2025. · NCT05892614

Studije za Skleroderma u drugim gradovima

Ostale studije u gradu Chicago

Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.